Clearmind Medicine Inc. (NASDAQ: CMND) shares are trading higher on Tuesday after the company announced results from its weight loss and metabolic disorder program.
What To Know: The company announced positive results from its pre-clinical trial, which utilized a treatment which combined Clearmind's MEAI and SciSparc's Palmitoylethanolamide (PEA). The trial aimed to determine the most effective dosage for the combination, assessing its safety and examining its impact on several metabolic and behavioral factors.
"We are excited by these latest results of our combination treatment for obesity ...